A Real-World Study of Bispecific Antibodies in Multiple Myeloma - Trial NCT06359067
Access comprehensive clinical trial information for NCT06359067 through Pure Global AI's free database. This phase not specified trial is sponsored by Assistance Publique - Hôpitaux de Paris and is currently Completed. The study focuses on Multiple Myeloma. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Treated by bispecific antibodies, teclistamab or elranatamab in usual care
Observational
other
Sponsor & Location
Assistance Publique - Hôpitaux de Paris
Timeline & Enrollment
N/A
Jul 01, 2022
Dec 31, 2023
Primary Outcome
Infection rate
Summary
Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for
 patients with multiple myeloma who are refractory to all current drugs. The results are very
 encouraging but complicated adverse events, particularly infectious. This study analyzes
 survival data in patients treated with BsAb, as well as safety data, in particular the
 proportions and locations of infectious events. The results are compared to a control cohort.
 This study is multicentric on all the university hospitals of Paris (AP-HP).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06359067
Non-Device Trial